微创手术与单纯内科治疗幕上脑出血的MIND随机临床试验
MIND为开放标签、多中心随机临床试验,将幕上自发性脑出血患者按2:1随机分配至微创手术联合内科治疗或单纯内科治疗。因同期另一项ICH试验阳性结果触发独立可行性分析,入组提前终止于236例;180天改良Rankin量表序数分析未显示微创手术优于内科治疗。
要点
- 微创手术未显著改善180天死亡与残疾复合结局(OR 1.03;96%CI 0.62-1.72;P=.45)。
- 30天死亡率手术组7.2%、内科组9.8%,差异-2.5%(95%CI -11.7%至4.8%)。
- 试验因外部阳性结果提前终止,仅随机236例,效力受限。
核心结论
- 在幕上自发性脑出血患者中,发病72小时内微创手术未显著降低30天死亡率,也未显著改善180天残疾结局。
研究设计与样本
- 开放标签、多中心随机临床试验,按2:1随机分配至微创手术联合内科治疗或单纯内科治疗。
- 2018年2月6日至2023年8月28日在全球32个中心入组,共随机236例(手术154例、内科82例),因独立可行性分析提前终止。
主要发现
- 主要疗效模型分析未显示微创手术优于内科治疗(OR 1.03;96%CI 0.62-1.72;P=.45)。
- 校正模型平均OR为1.10(96%CI 0.66-1.85;P=.35),亦无统计学意义。
- 30天死亡:手术组11例(7.2%),内科组8例(9.8%),差异-2.5%(95%CI -11.7%至4.8%)。
关键数值与推荐
- 入组条件:年龄18-80岁、幕上自发性ICH血肿量20-80 mL、基线NIHSS≥6、GCS 5-15。
- 干预时机:症状发作72小时内行微创手术(Artemis Neuro Evacuation Device)联合内科治疗。
- 主要疗效结局:180天改良Rankin量表(0-6分)序数分析的死亡与残疾复合结局;主要安全结局为30天死亡率。
临床怎么用
- 对幕上自发性脑出血,微创手术不宜作为常规优于内科治疗的推荐,需结合个体情况并与家属充分沟通。
- 该试验因提前终止效力不足,阴性结果不应完全否定微创手术,临床决策仍需参考更多证据。
局限性
- 入组提前终止,仅随机236例,统计效力受限。
- 为开放标签设计,可能存在评价偏倚。
- 样本以深部出血为主(69.5%),结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It remains uncertain whether surgical evacuation improves functional outcomes in patients with supratentorial intracerebral hemorrhage (ICH). OBJECTIVE: To compare the safety and efficacy of minimally invasive surgery with the Artemis Neuro Evacuation Device to guideline-based medical management alone for spontaneous supratentorial ICH. DESIGN, SETTING, AND PARTICIPANTS: The MIND open-label, multicenter randomized clinical trial randomized patients with spontaneous supratentorial ICH in a 2:1 ratio to either minimally invasive surgery or medical management alone. Participants were enrolled at 32 participating global sites between February 6, 2018, and August 28, 2023. This article reports on the primary trial outcome. Of 4066 eligible adult patients (aged 18-80 years) with moderate- to large-volume supratentorial ICH (20-80 mL), baseline National Institutes of Health Stroke Scale score of 6 or higher, and Glasgow Coma Scale score between 5 and 15, 154 were randomized to minimally invasive surgery and 82 to medical management. Data were analyzed from February to September 2024. INTERVENTION: Minimally invasive surgery (within 72 hours of symptom onset) plus medical management or medical management alone. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was 180-day combined death and disability via ordinal modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]). The primary safety outcome was 30-day mortality. RESULTS: Following an independent feasibility analysis prompted by the publication of positive results of a contemporaneous ICH trial, enrollment was stopped early at 236 participants. Overall median (IQR) participant age was 60 (50-70) years, 87 participants (36.9%) were female, 164 (69.5%) had primarily deep bleeds, and 72 (30.5%) had primarily lobar bleeds. Efficacy results of the primary model analysis suggested lack of evidence for the superiority of minimally invasive surgery over medical management (odds ratio [OR], 1.03; 96% CI, 0.62-1.72; P = .45). The adjusted model's mean OR was also nonsignificantly greater than 1 (OR, 1.10; 96% CI, 0.66-1.85; P = .35). By 30 days, 11 participants (7.2%) in the surgery group and 8 (9.8%) in the medical management group died (difference, -2.5%; 95% CI, -11.7% to 4.8%). CONCLUSIONS AND RELEVANCE: In the MIND randomized clinical trial, minimally invasive surgery within 72 hours did not significantly reduce 30-day mortality or improve 180-day disability in patients with supratentorial ICH compared to medical management alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03342664.
引用
- Arthur AS, Jahromi BS, Saphier PS, et al. Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage: The MIND Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 40892424. doi:10.1001/jamaneurol.2025.3151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。